Gilead Sciences, Inc. which can be found using ticker (GILD) now have 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $113.92 and $64.96 and has a mean target at $79.65. Now with the previous closing price of $66.93 this would imply there is now a potential upside of 19.0%. It’s also worth noting that there is a 50 day moving average of $72.17 and the 200 day moving average is $76.65. The company has a market cap of 82.50B. The stock price for the company is currently $66.16 USD
The potential market cap would be $98,178,514,129 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 14.7, revenue per share of $21.73 and a 9.78% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
